Skip to main content
    T

    Tarsus Pharmaceuticals Inc (TARS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $78.68
    -1.60 (-1.99%)

    Market Cap: $3.96B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Tarsus Pharmaceuticals Inc (TARS) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Tarsus Pharmaceuticals (TARS) trades at 5.4x sales and 35.1x book value. Its P/S of 5.4x is below its 5-year median of 11.5x. Its forward P/E is 66.7x.

    Current Multiples

    Its free cash flow yield is 0.9%.

    MultipleValue
    P/E (trailing)N/A
    Forward P/E66.7x
    Price to sales5.4x
    Price to book35.1x
    Price to FCF112.6x
    EV/FCF110.6x
    PEGN/A
    FCF yield0.9%
    As of Nov 17, 2026

    Historical Medians

    MultipleCurrent5-year median10-year median
    P/S5.4x11.5xN/A
    P/B35.1x4.2xN/A
    Medians of month-end values through Oct 2026: 60 months (5-year).

    Valuation History

    Over the 5 of the 6 year ends shown that have a P/S, its P/S ranged from 7.6x in 2025 to 35.9x in 2023. 2025 was the lowest of those years.

    Year endPriceP/SP/B
    2025$81.887.6x10.2x
    2024$55.3711.4x9.5x
    2023$20.2535.9x3.3x
    2022$14.6614.1x2.0x
    2021$22.508.1x2.8x
    2020$41.33N/A5.2x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About TARS

    What is TARS's forward P/E ratio?

    Tarsus Pharmaceuticals has a forward P/E ratio of 66.7x.

    What is TARS's price to sales ratio?

    Tarsus Pharmaceuticals has a price to sales ratio of 5.4x.